电子烟联合咨询与单独咨询对戒烟效果的随机临床试验
该随机临床试验纳入376名有戒烟意愿的成人,比较尼古丁电子烟、非尼古丁电子烟联合个体咨询与单独咨询的戒烟效果。主要终点为12周时经生化验证的7天点戒烟率,尼古丁电子烟联合咨询显著高于单独咨询(21.9% vs 9.1%),但24周时差异不再显著;非尼古丁电子烟联合咨询在12周无显著差异,24周时显著更高。试验因生产延迟提前终止,解读受限。
要点
- 尼古丁电子烟联合咨询在12周显著提高戒烟率,但24周时优势消失。
- 非尼古丁电子烟联合咨询在12周无显著差异,24周时戒烟率显著高于单独咨询。
- 试验提前终止且两种电子烟结果不一致,需进一步研究验证。
核心结论
- 尼古丁电子烟联合咨询相比单独咨询在12周显著提高点戒烟率,但24周时差异不显著。
- 非尼古丁电子烟联合咨询在12周与单独咨询无显著差异,但在24周时显著更高。
研究设计与样本
- 随机临床试验,2016年11月至2019年9月在加拿大17个中心纳入有戒烟意愿的成人。
- 筛查801人,274人不符合条件,151人拒绝,最终随机376人(目标486人的77%),因生产延迟提前终止。
- 随机分为尼古丁电子烟组(n=128)、非尼古丁电子烟组(n=127)和无电子烟组(n=121),均接受个体咨询,干预12周,随访至24周。
主要发现
- 12周点戒烟率:尼古丁电子烟联合咨询21.9% vs 单独咨询9.1%,风险差12.8(95%CI 4.0-21.6)。
- 24周点戒烟率:尼古丁电子烟联合咨询17.2% vs 单独咨询9.9%,风险差7.3(95%CI -1.2-15.7)。
- 12周点戒烟率:非尼古丁电子烟联合咨询17.3% vs 单独咨询9.1%,风险差8.2(95%CI -0.1-16.6)。
- 24周点戒烟率:非尼古丁电子烟联合咨询20.5% vs 单独咨询9.9%,风险差10.6(95%CI 1.8-19.4)。
- 不良事件常见:尼古丁电子烟联合咨询组120例(94%),非尼古丁电子烟联合咨询组118例(93%),单独咨询组88例(73%);最常见为咳嗽(64%)和口干(53%)。
关键数值与推荐
- 主要终点为12周时经呼出气一氧化碳生化验证的7天点戒烟率(因提前终止由52周更改)。
- 缺失数据假定为继续吸烟。
临床怎么用
- 对于有戒烟意愿的成人,尼古丁电子烟联合咨询可在短期内提高戒烟率,但长期效果不明确。
- 非尼古丁电子烟联合咨询的长期戒烟效果需进一步研究,临床决策应结合患者偏好和安全性。
局限性
- 试验因生产延迟提前终止,样本量仅为目标的77%,可能影响统计效能。
- 尼古丁与非尼古丁电子烟结果不一致,且24周时尼古丁电子烟优势消失,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial. OBJECTIVE: To evaluate e-cigarettes with individual counseling for smoking cessation. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial enrolled adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites (801 individuals screened; 274 ineligible and 151 declined). Manufacturing delays resulted in early termination (376/486 participants, 77% of target). Outcomes through 24 weeks (March 2020) are reported. INTERVENTIONS: Randomization to nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for 12 weeks. All groups received individual counseling. MAIN OUTCOMES AND MEASURES: The primary end point was point prevalence abstinence (7-day recall, biochemically validated using expired carbon monoxide) at 12 weeks, changed from 52 weeks following early termination. Participants missing data were assumed to be smoking. The 7 secondary end points, examined at multiple follow-ups, were point prevalence abstinence at other follow-ups, continuous abstinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to adverse effects, and treatment adherence. RESULTS: Among 376 randomized participants (mean age, 52 years; 178 women [47%]), 299 (80%) and 278 (74%) self-reported smoking status at 12 and 24 weeks, respectively. Point prevalence abstinence was significantly greater for nicotine e-cigarettes plus counseling vs counseling alone at 12 weeks (21.9% vs 9.1%; risk difference [RD], 12.8 [95% CI, 4.0 to 21.6]) but not 24 weeks (17.2% vs 9.9%; RD, 7.3 [95% CI, -1.2 to 15.7]). Point prevalence abstinence for nonnicotine e-cigarettes plus counseling was not significantly different from counseling alone at 12 weeks (17.3% vs 9.1%; RD, 8.2 [95% CI, -0.1 to 16.6]), but was significantly greater at 24 weeks (20.5% vs 9.9%; RD, 10.6 [95% CI, 1.8 to 19.4]). Adverse events were common (nicotine e-cigarette with counseling: 120 [94%]; nonnicotine e-cigarette with counseling: 118 [93%]; counseling only: 88 [73%]), with the most common being cough (64%) and dry mouth (53%). CONCLUSIONS AND RELEVANCE: Among adults motivated to quit smoking, nicotine e-cigarettes plus counseling vs counseling alone significantly increased point prevalence abstinence at 12 weeks. However, the difference was no longer significant at 24 weeks, and trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02417467.
引用
- Eisenberg MJ, Hébert-Losier A, Windle SB, et al. Effect of e-Cigarettes Plus Counseling vs Counseling Alone on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2020. PMID: 33170240. doi:10.1001/jama.2020.18889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。